Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
King of Prussia, PA--August 12, 2005--A review article published in the July/August 2005 Journal of Infusion Nursing examines the need for established treatment guidelines to support doctors and ...
"[O]ur study, which has the largest cohort to date, did not show an increased rate of VTEs in patients with DM on IVIG. Therefore, it is safe to start patients on this medicine as it is one of our ...
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment trials ...
TEANECK, N.J., July 16, 2025 /PRNewswire/ -- GC Biopharma USA, Inc., a leader in plasma-derived products, announced the presentation of new data on the viscosity of several commercially available 10% ...
With use of intravenous immune globulin (IVIg) for the treatment of adults with dermatomyositis, a significantly higher percentage of patients experienced at least minimal improvement in disease ...
*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Dear Dr. Roach • My brother has been treated for peripheral neuropathy for the past 10 years. He turns 60 in October. After an ...
BACKGROUND: Current prescribing information recommends that physicians apply a dose ratio of 1.37:1 (1.53:1 prior to January 2015) in the United States (US) when switching patients with primary ...
Data presented at biennial ESID meeting reveal pharmacoeconomic benefits of switching from IVIG to SCIg in primary immunodeficiency FLORENCE, Italy, Oct. 4, 2012 /CNW/ - Analysis using a new economic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback